Literature DB >> 33800944

MicroRNA as Epigenetic Modifiers in Endometrial Cancer: A Systematic Review.

Amélia Favier1,2,3, Grégoire Rocher2,3, Annette K Larsen1, Romain Delangle2, Catherine Uzan1,2, Michèle Sabbah1, Mathieu Castela4, Alex Duval3, Céline Mehats5, Geoffroy Canlorbe1,2.   

Abstract

The objective of this systematic review is to summarize our current knowledge on the influence of miRNAs in the epigenetic deregulation of tumor-related genes in endometrial cancer (EC). We conducted a literature search on the role of miRNAs in the epigenetic regulation of EC applying the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The following terms were used: microRNA, miRNA, miR, endometrial cancer, endometrium, epigenetic, epimutation, hypermethylation, lynch, deacetylase, DICER, novel biomarker, histone, chromatin. The miRNAs were classified and are presented according to their function (tumor suppressor or onco-miRNA), their targets (when known), their expression levels in EC tissue vs the normal surrounding tissue, and the degree of DNA methylation in miRNA loci and CpG sites. Data were collected from 201 articles, including 190 original articles, published between November 1, 2008 and September 30, 2020 identifying 313 different miRNAs implicated in epigenetic regulation of EC. Overall, we identified a total of 148 miRNAs with decreased expression in EC, 140 miRNAs with increased expression in EC, and 22 miRNAs with discordant expression levels. The literature implicated different epigenetic phenomena including altered miRNA expression levels (miR-182, -230), changes in the methylation of miRNA loci (miR-34b, -129-2, -130a/b, -152, -200b, -625) and increased/decreased methylation of target genes (miR-30d,-191). This work provides an overview of all miRNAs reported to be involved in epigenetic regulation in EC including DNA methylation and RNA-associated silencing. These findings may contribute to novel strategies in diagnosis, risk assessment, and treatments aimed at miRNAs, their target genes or DNA methylation.

Entities:  

Keywords:  Endometrial cancer; Epigenetics; Methylation; MicroRNA; miR-129-2; miR-130a/b; miR-182; miR-191; miR-200b; miR-230

Year:  2021        PMID: 33800944      PMCID: PMC7961497          DOI: 10.3390/cancers13051137

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  183 in total

1.  FAM98A promotes cancer progression in endometrial carcinoma.

Authors:  Zenghui Li; Ning Li; Xiaomei Sun; Jing Wang
Journal:  Mol Cell Biochem       Date:  2019-05-21       Impact factor: 3.396

2.  Identification of a Multi-RNA-Type-Based Signature for Recurrence-Free Survival Prediction in Patients with Uterine Corpus Endometrial Carcinoma.

Authors:  Peizhi Wang; Zhi Zeng; Xiaoting Shen; Xiaohui Tian; Qingjian Ye
Journal:  DNA Cell Biol       Date:  2020-02-27       Impact factor: 3.311

3.  MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes.

Authors:  Chiara Braconi; Nianyuan Huang; Tushar Patel
Journal:  Hepatology       Date:  2010-03       Impact factor: 17.425

4.  MicroRNA-137 promoter methylation is associated with poorer overall survival in patients with squamous cell carcinoma of the head and neck.

Authors:  Scott M Langevin; Roslyn A Stone; Clareann H Bunker; Maureen A Lyons-Weiler; William A LaFramboise; Lori Kelly; Raja R Seethala; Jennifer R Grandis; Robert W Sobol; Emanuela Taioli
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

5.  RNA polymerase III transcribes human microRNAs.

Authors:  Glen M Borchert; William Lanier; Beverly L Davidson
Journal:  Nat Struct Mol Biol       Date:  2006-11-12       Impact factor: 15.369

6.  miR-27b-3p/MARCH7 regulates invasion and metastasis of endometrial cancer cells through Snail-mediated pathway.

Authors:  Ling Liu; Jianguo Hu; Tinghe Yu; Shuang You; Yulin Zhang; Lina Hu
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2019-05-23       Impact factor: 3.848

Review 7.  Prognostic Value of MicroRNA-182 in Cancers: A Meta-Analysis.

Authors:  Fei Wang; Shanliang Zhong; Haijun Zhang; Wei Zhang; Hongming Zhang; Xue Wu; Baoan Chen
Journal:  Dis Markers       Date:  2015-05-07       Impact factor: 3.434

8.  Genome-wide DNA methylation sequencing reveals miR-663a is a novel epimutation candidate in CIMP-high endometrial cancer.

Authors:  Megumi Yanokura; Kouji Banno; Masataka Adachi; Daisuke Aoki; Kuniya Abe
Journal:  Int J Oncol       Date:  2017-04-19       Impact factor: 5.650

9.  Superparamagnetic iron oxide nanoparticle-mediated expression of miR-326 inhibits human endometrial carcinoma stem cell growth.

Authors:  Yongtao Gao; Haiyang Qian; Xue Tang; Xiling Du; Gang Wang; Hairong Zhang; Fei Ye; Te Liu
Journal:  Int J Nanomedicine       Date:  2019-04-18

10.  Cullin-5, a ubiquitin ligase scaffold protein, is significantly underexpressed in endometrial adenocarcinomas and is a target of miR-182.

Authors:  Eric J Devor; Brandon M Schickling; Henry D Reyes; Akshaya Warrier; Brittany Lindsay; Michael J Goodheart; Donna A Santillan; Kimberly K Leslie
Journal:  Oncol Rep       Date:  2016-02-01       Impact factor: 3.906

View more
  3 in total

Review 1.  Clinical Value and Molecular Function of Circulating MicroRNAs in Endometrial Cancer Regulation: A Systematic Review.

Authors:  Joy Bloomfield; Michèle Sabbah; Mathieu Castela; Céline Mehats; Catherine Uzan; Geoffroy Canlorbe
Journal:  Cells       Date:  2022-06-03       Impact factor: 7.666

Review 2.  MicroRNAs in the Regulation of Endometrial Receptivity for Embryo Implantation.

Authors:  Manizha Shekibi; Sophea Heng; Guiying Nie
Journal:  Int J Mol Sci       Date:  2022-06-01       Impact factor: 6.208

Review 3.  Can miRNAs be useful biomarkers in improving prognostic stratification in endometrial cancer patients? An update review.

Authors:  Gloria Ravegnini; Francesca Gorini; Eugenia De Crescenzo; Antonio De Leo; Dario De Biase; Marco Di Stanislao; Patrizia Hrelia; Sabrina Angelini; Pierandrea De Iaco; Anna Myriam Perrone
Journal:  Int J Cancer       Date:  2021-11-17       Impact factor: 7.316

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.